Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary phage-based platform, ImmunoPhage, that enables the rapid generation of immune activating agents that fully engage the immune system.
Market
Cancer and infectious diseases
Location
Rockville,
MD,
USA
Coinvestors
Apeiron Investment Group, Cambrian Biopharma, Catalio Capital Management, Future Ventures, Moore Strategic Ventures, Presight Capital, Pura Vida Investments